Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer.

ABSTRACT:

Purpose

Over the past decades, there is a dramatic rise in the mortality and incidence rates of breast cancer globally, despite the progressive advancement of therapeutic options. Late detection of breast cancer is often the main culprit for the ineffective treatment, and death in patients. Finding breast cancer biomarkers is thus of significant importance. Epigenetic modifications are associated with up and down regulation of important biomarker in the TGF-β pathway, such as SMAD4, which may have a greater impact in the growth and poor prognosis in breast cancer. In the current investigation we are going to check how SMAD4 regulate in various Breast cancer patients? And how its epigenetic modifications play crucial role in disease prognosis?

Methods

Twenty eight samples of

SUBMITTER: Chaudhary A 

PROVIDER: S-EPMC12328851 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature